高危PCI使用Impella机械循环支持的1年结局:倾向评分匹配分析
该研究比较Impella辅助高危经皮冠状动脉介入治疗(HR-PCI)与无机械循环支持HR-PCI的1年结局。结果显示两组1年出院后全因死亡率、卒中和重复血运重建相似,Impella组心肌梗死发生率更低。
要点
- Impella辅助HR-PCI患者尽管心血管风险谱更差,1年生存率与无机械循环支持组相似。
- Impella组1年心肌梗死发生率显著低于对照组(1.4% vs. 10.9%)。
- Impella可能改善特定高危PCI患者的结局,仍需随机对照试验证实。
核心结论
- 尽管心血管风险谱更差,Impella辅助HR-PCI患者1年出院后生存率与无机械循环支持的倾向评分匹配对照组相似。
- Impella辅助HR-PCI患者心肌梗死发生率低于无机械循环支持组(1.4% vs. 10.9%,p=0.003)。
- Impella可能改善特定患者的HR-PCI结局,但需进一步随机对照试验证实。
研究设计与样本
- 对照组来自CardioSilesia回顾性注册研究中接受无机械循环支持HR-PCI的患者,采用倾向评分匹配。
- 研究终点包括1年出院后全因死亡率、心肌梗死、卒中、心力衰竭再住院和重复冠状动脉血运重建。
主要发现
- 匹配后两组临床和血管造影特征相当,但IMPELLA-PL队列血脂异常(78.3% vs. 37.7%,p<0.001)、慢性肾病(39.9% vs. 16.7%,p<0.001)和外周动脉疾病(34.1% vs. 8.0%,p<0.001)发生率更高。
- Impella支持患者更常使用血管内超声(44.2% vs. 25.4%,p=0.002),对照组分期血运重建更常见(30.4% vs. 15.9%,p=0.007)。
- 1年时两组出院后全因死亡率、卒中和重复冠状动脉血运重建发生率相似。
- IMPELLA-PL队列心肌梗死发生率较低(1.4% vs. 10.9%,p=0.003),心力衰竭再住院呈降低趋势(9.4% vs. 18.1%,p=0.055)。
关键数值与推荐
- Impella组心肌梗死发生率1.4%,对照组10.9%,p=0.003。
- Impella组心力衰竭再住院率9.4%,对照组18.1%,p=0.055。
- Impella组血脂异常78.3%,对照组37.7%,p<0.001。
- Impella组慢性肾病39.9%,对照组16.7%,p<0.001。
- Impella组外周动脉疾病34.1%,对照组8.0%,p<0.001。
临床怎么用
- 对于伴有复杂合并症的高危PCI患者,Impella辅助可作为机械循环支持的选择之一。
- Impella支持下可更频繁使用血管内超声进行优化,可能有助于降低心肌梗死风险。
局限性
- 回顾性注册研究设计,残余混杂不能完全排除。
- IMPELLA-PL队列基线风险谱更差,倾向评分匹配可能无法完全平衡未测量因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background Impella is increasingly used as mechanical circulatory support (MCS) during high-risk percutaneous coronary interventions (HR-PCI). Registry-based data provide insights into the efficacy and safety of Impella-assisted HR-PCI. Aims We aimed to evaluate 1-year outcomes of Impella-assisted HR-PCI compared to HR-PCI without MCS. Methods One hundred and thirty-eight patients undergoing Impella-assisted PCI, included in the IMPELLA-PL registry, were propensity score-matched with controls from the retrospective CardioSilesia registry who underwent HR-PCI without MCS. Study endpoints included 1-year post-discharge all-cause mortality, myocardial infarction (MI), stroke, rehospitalization for heart failure (HF), and repeat coronary revascularization. Results Clinical and angiographic characteristics were comparable in both groups, with higher rates of dyslipidemia (78.3% vs. 37.7%, p < 0.001), chronic kidney disease (39.9% vs. 16.7%, p < 0.001), and peripheral artery disease (34.1% vs. 8.0%, p < 0.001) in the IMPELLA-PL cohort. Intravascular ultrasound was more frequently used in the Impella-supported patients (44.2% vs. 25.4%, p = 0.002), while staged revascularization was more common among controls (30.4% vs. 15.9%, p = 0.007). At 1 year, rates of post-discharge all-cause mortality, stroke, and repeat coronary revascularization were similar in both groups. MI was less frequent in the IMPELLA-PL cohort (1.4% vs. 10.9%, p = 0.003), alongside a trend toward lower incidence of rehospitalizations for HF (9.4% vs. 18.1%, p = 0.055). Conclusions Despite an unfavorable cardiovascular risk profile, patients who underwent Impella-assisted HR-PCI had similar 1-year post-discharge survival, with a lower rate of MI, compared to propensity score-matched controls who underwent HR-PCI without MCS. Impella may improve HR-PCI outcomes in selected patients, but further randomized controlled trials are required to confirm this finding.
引用
- Catheterization and Cardiovascular Interventions:One‐Year Outcomes of High‐Risk Percutaneous Coronary Interventions With Versus Without Mechanical Circulatory Support: Propensity Score‐Matched Analysis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。